Ioachimescu Octavian C, Ioachimescu Adriana G, Iannini Paul B
Department of Pulmonary, Allergy and Critical Care, Cleveland Clinic Foundation, 9500 Euclid Ave., A90 Cleveland, OH 44195, USA.
Int J Antimicrob Agents. 2004 Nov;24(5):485-90. doi: 10.1016/j.ijantimicag.2004.05.006.
Multiple severity scoring systems have been devised and evaluated in community-acquired pneumonia (CAP), but a simplified set of prognostic indicators has not yet been developed. Streptococcus pneumoniae is the most frequent aetiological agent of CAP. Our aim was to characterise the outcome in the light of different severity scoring systems and to compare the predictive values of different sets of clinical parameters, using available clinical data for pneumococcal CAP patients. This is a case series retrospective analysis that included consecutive adult pneumococcal CAP patients admitted to Danbury Hospital between 1 January 1996 and 31 December 2000. The aetiology was confirmed by positive sputum and/or blood cultures. The severity assessment included the Pneumonia Outcome Research Trial (PORT) and British Thoracic Society (BTS) scoring systems and other additional parameters. Primary end-points were in-hospital CAP-attributable deaths and length of hospitalisation. N = 151 patients with S. pneumoniae CAP were identified. The mean (+/- standard deviation) age at the time of diagnosis was 68 (+/-15) years. Thirty-three patients (22%) were admitted to the medical intensive care unit. The mean (median) hospitalisation duration was 7.5 (+/-5) days. Door-to-antibiotic mean (median) administration time was 3.7 (2) hours. Most frequent antibiotics used initially were cephalosporins plus/minus macrolides or fluoroquinolones. The mean (+/- standard deviation) PORT score was 105 (+/-37). The observed CAP-related mortality was 9/151 (5.9%, 95% confidence interval: 3-9%). The mortality rate in ICU was 18% (6/33). Sixty-nine patients (45%) had S. pneumoniae bacteraemia an admission. The bacteraemic and non-bacteraemic patients had similar PORT scores (107 vs. 104, P = 0.66), length of hospitalisation (8 vs. 7 days, P = 0.41) and mortality rates (9% vs. 4%, P = 0.30). In conclusion, patients admitted with pneumococcal CAP, although severe and with multiple co-morbidities had low in-hospital mortality rates and lengths of hospitalisation. Neither prior antimicrobial use (or failure) nor antimicrobial resistance contributed to an adverse outcome. S. pneumoniae bacteraemia failed to correlate with need for ICU, length of stay, higher morbidity index or fatal outcome. Low rates of empirical antibiotic use for non-bacterial infections in the local community, implementation of an emergency department protocol for CAP therapy, early recognition of higher risk patients and placement in ICU, use of broad spectrum antibiotics, infectious disease approval or critical pathway restriction for admission orders, could all have combined to effect a good outcome for these patients.
针对社区获得性肺炎(CAP),人们已经设计并评估了多种严重程度评分系统,但尚未开发出一套简化的预后指标。肺炎链球菌是CAP最常见的病原体。我们的目的是根据不同的严重程度评分系统来描述结局,并使用肺炎球菌CAP患者的现有临床数据比较不同临床参数集的预测价值。这是一项病例系列回顾性分析,纳入了1996年1月1日至2000年12月31日期间连续入住丹伯里医院的成年肺炎球菌CAP患者。病因通过痰和/或血培养阳性得以证实。严重程度评估包括肺炎结局研究试验(PORT)和英国胸科学会(BTS)评分系统以及其他附加参数。主要终点是住院期间CAP归因死亡和住院时间。共识别出151例肺炎球菌CAP患者。诊断时的平均(±标准差)年龄为68(±15)岁。33例患者(22%)入住了医学重症监护病房。平均(中位数)住院时间为7.5(±5)天。从就诊到使用抗生素的平均(中位数)给药时间为3.7(2)小时。最初最常用的抗生素是头孢菌素加/减大环内酯类或氟喹诺酮类。PORT评分的平均(±标准差)为105(±37)。观察到的与CAP相关的死亡率为9/151(5.9%,95%置信区间:3 - 9%)。ICU中的死亡率为18%(6/33)。69例患者(45%)入院时存在肺炎链球菌菌血症。菌血症患者和非菌血症患者的PORT评分相似(107对104,P = 0.66),住院时间相似(8天对7天,P = 0.41),死亡率也相似(9%对4%,P = 0.30)。总之,肺炎球菌CAP患者尽管病情严重且合并多种疾病,但住院死亡率和住院时间较低。既往抗菌药物使用(或治疗失败)以及抗菌药物耐药性均未导致不良结局。肺炎链球菌菌血症与入住ICU的需求、住院时间、更高的发病指数或致命结局无关。当地社区非细菌感染的经验性抗生素使用率较低、实施了CAP治疗急诊科方案、早期识别高危患者并入住ICU、使用广谱抗生素、传染病专家批准或对入院医嘱进行关键路径限制,所有这些因素共同作用可能促成了这些患者的良好结局。